Survivin is expressed in many cancers but not in normal adult tissues and is transcriptionally regulated. To test the feasibility of using the survivin promoter to induce cancer-specific transgene expression in lung cancer gene therapy, a vector expressing a luciferase gene driven by the survivin promoter was constructed and evaluated in vitro and in vivo. We found that the survivin promoter was generally more highly activated in cancer cell lines than in normal and immortalized normal cell lines. When delivered intravenously by DNA:liposome complexes, the survivin promoter was more than 200 times more cancer specific than the cytomegalovirus promoter in vivo. To identify lung cancer patients who may benefit from gene therapy with the survivin promoter, we measured survivin protein expression in surgical specimens of 75 non-small-cell lung cancers and 10 normal lung tissues by immunohistochemical staining and found that survivin is expressed in most of the non-small-cell lung cancers tested (81%, 61 of 75) but none of the normal lung tissues. The survivin promoter also induced transgene expression of a mutant Bik in cancer cells, which suppressed the growth of cancer cells in vitro and in vivo. These results indicate that the survivin promoter is a cancerspecific promoter for various cancers and that it may be useful in cancer gene therapy.
L ung cancer is one of the leading causes of death worldwide. 1 Survival has not substantially increased recently, although vigorous efforts have been made to improve it. As the pathogenesis and biology of tumors are becoming clear, gene therapy could be an effective alternative for the treatment of lung cancer. Nonviral gene delivery systems such as cationic lipids are attractive strategies for therapeutic application because of their minimal immunogenicity and low toxicity in vivo. (N-[1-(2,3-Dioleoyloxy)]-N,N,N-trimethylammonium propane methylsulfate (DOTAP):cholesterol (Chol) cationic liposomes have been reported to be good preparations for mediating efficient gene transfer to various organs, especially to the lungs. 2, 3 One study showed that therapeutic tumor suppressor genes delivered by this improved liposome vector can inhibit primary and disseminated human non-small-cell lung cancers in animal models. 3 Most gene therapy approaches currently use nonspecific, nonselective prokaryotic promoters such as the cytomegalovirus (CMV) promoter that can be expressed at high levels in normal cells, potentially contributing to toxicity. This is particularly true when cytotoxic or strongly apoptotic genes are used. For cancer-specific expression of cytotoxic or apoptotic genes, a better approach would be to use a tissue-or cancer-specific promoter to limit the spectrum of cells that express the gene therapy construct. 4, 5 Possible for such therapy, survivin is a member of the inhibitor of apoptosis (IAP) family. Survivin is overexpressed in common cancers but not in normal adult tissues. [6] [7] [8] Survivin mRNA or protein overexpression (compared with normal tissues) was demonstrated in tumors of the lung, 9,10 breast, 11 colon, 12 stomach, 13 esophagus, 14 pancreas, 15 bladder, 16 uterus, 17 ovaries 18 and skin, 19 and in lymphoma 20 and leukemia. 21 Transcription experiments indicated that survivin protein expression in cancer tissue appears to be regulated, at least in part, transcriptionally. 22, 23 In a genomewide search, survivin constituted the fourth top ''transcriptome'' in cancers of lung, colon, and brain and melanoma, but was weakly expressed or undetectable in the same normal tissues. 24 Analyses of survivin mRNA expression levels in non-small-cell lung cancers (NSCLC) also revealed a strong survivin mRNA upregulation in nearly all tumor samples compared with nontumor controls. 10, 25 As a result of the cancer-specific expression of survivin, some groups have developed antisense RNA 26 or dominant-negative mutant protein 27 for cancer therapy. 28 However, cancer-selective activation of the survivin promoter in vivo has not been demonstrated, and the survivin promoter has not been used in cancer gene therapy.
Bik is a proapoptotic member of the Bcl-2 gene family, which triggers apoptosis through a p53-independent pathway. 29, 30 Previously, we have shown the effectiveness of tumor suppression by systemic delivery of Bik:liposome complexes. 31 We have also demonstrated that a mutant form of Bik (BikDD) is more potent than the wild-type Bik in killing cancer cells. 32 Since survivin is generally strongly expressed in cancer cells but repressed in most normal cells and because its expression is regulated at the transcriptional level, we tested whether the survivin promoter can be used in lung cancer gene therapy. We examined the specificity of survivin promoter activation in lung cancers and the prevalence of survivin expression in lung cancer specimens. We also evaluated the tumor-inhibitory effect of the proapoptotic gene BikDD under the control of the survivin promoter.
Materials and methods

Liposomes and cell lines
DOTAP:Chol stock solution (20 mM) was prepared by the Non-Viral Core facility at the Baylor College of Medicine (Houston, TX) directed by Nancy Smyth Templeton. The human cancer cell lines H1437, H358, H1435, H322, and H1299 (non-small-cell lung cancer); HeLa (cervical cancer); and HT29 (colon cancer) and the normal and immortalized normal cell lines WI-38 (normal lung fibroblast) and 184A1 (normal mammary epithelial cells, chemically immortalized) were purchased from the American Type Culture Collection (Manassas, VA) and cultured according to the vendor's instruction.
Construction of Plasmids
Four different plasmids were constructed (Fig 1) . To make the luciferase expression plasmid under the control of the survivin promoter (pSRVN-Luc), we generated a 977-base-pair (bp) fragment of the human survivin gene promoter (nucleotides 1824-2800, GenBank Accession Number U75285) by polymerase chain reaction of human bacterial artificial chromosome libraries (RPC 1-11 
Transient transfection and reporter assays
To normalize transfection efficiency, we used the DualLuciferase reporter assay system according to the manufacturer's instructions (Promega). The dual luciferase assay is a widely used technique. 33, 34 In this system, the plasmid pRL-TK that contains the Renilla luciferase gene under the control of the thymidine kinase promoter is cotransfected as an internal control. In our previous study 33 and preliminary tests, the survivin and CMV promoters have no obvious effects on the transgene expression of the thymidine kinase promoter. Cells were grown in six-well plates with the suggested medium until 60-80% confluent. Then, the cells were transiently transfected with 1.5 mg of tested plasmid DNA along with 0.1 mg of pRL-TK using 1.6 ml of liposomes (DOTAP:-Chol, 8 mM) in 200 ml of Opti-Medium (Life Technology) per well for 4-6 hours. Cell lysates were prepared 48 hours after transfection for the dual luciferase assay by following the manufacturer's instructions (Promega) and using a TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA). The dual luciferase ratio was defined as the luciferase activity of the tested plasmids divided by the luciferase activity of pRL-TK. 
Preparation of DNA:liposome mixtures for animal studies
DNA:liposome complexes were prepared fresh 2-3 hours before tail vein or intratumoral injection into mice as previously described. 2 Briefly, DOTAP:Chol (20 mM) stock solution and stock DNA solution were diluted in 5% dextrose in water (D5W) and mixed in equal volumes to make a final solution of 4 mM DOTAP:Chol and 150 mg DNA in 300 ml of solution (liposome:DNA ratio 1:2.6). All reagents were diluted and mixed at room temperature in a 1.5-ml Eppendorf tube. The DNA solution was added at the surface of the liposome and mixed rapidly up and down twice with the pipet tip. The DNA:liposome mixture was precipitate free and used for all in vivo experiments.
Establishment of tumors
Before the start of the animal experiments, nu/nu mice (18-22 g; Charles River Laboratories, Wilmington, MA) were subjected to 3.5 Gy of total body irradiation from a cesium source to increase tumor uptake. All of the mice were cared for according to the Guide for the Care and Use of Laboratory Animals (NIH publication number 85-23) and the institutional guidelines of The University of Texas MD Anderson Cancer Center. Then, 5 Â 10 6 H1299 cells were inoculated subcutaneously into the right dorsal flanks of 6-to 8-week old nu/nu mice to establish tumors.
Tissue distribution of the liposome-delivered reporter genes
H1299 cells were subcutaneously inoculated into the right dorsal flank of the nude mice. After 14 days until the tumor size reached 6-8 mm, the tumor-bearing mice received a single injection of 100 ml of DNA:liposome complexes containing 50 mg of DNA through the tail vein using a 29-gauge syringe needle. At 48 hours after injection, the mice were killed, and the tumors and other organs were resected and immediately frozen on dry ice. The tissues were homogenized after adding 1 Â passive lysis buffer (Promega Corp., Madison, WI) with a volume (ml) equivalent to 10 times the tissue weight (mg). After undergoing a freeze-thaw procedure, the tissue suspension was centrifuged at 12,000 r.p.m., 41C, for 3 minutes and the supernatant was collected for measurement of luciferase activity and protein concentration. The luciferase activity in the tissue supernatant was measured using a Lumat LB9507 instrument (Berthod, Bad Wildbad Germany). The luciferase activity (relative light unit, RLU) per mg protein was used to compare gene expression in different tissues. The background levels of luciferase activity in tumor and organs were measured using three tumor-bearing mice with intravenous injection of empty plasmid-liposome complexes. Protein concentrations were determined by using Bio-Rad protein assay reagent (Bio-Rad, Fremont, CA).
Tumor samples and immunohistochemical staining
Archived surgical specimens from 75 non-small-cell lung cancers (46 adenocarcinomas, 24 squamous cell carcinomas, and five adenosquamous carcinomas) and 10 normal lung tissues (obtained at least 5 cm from the tumor or from a different lobe of the involved lung) were analyzed in this study. Expression of survivin was evaluated by immunohistochemical staining. Briefly, after deparaffinization and antigen retrieval, 5 mm tissue sections were incubated overnight at 41C with polyclonal antisurvivin antibody (diluted 1:200, NOVUS Biologicals Inc., Littleton, CO). The sections were then incubated with biotinylated goat antirabbit immunoglobulin G (Vector Laboratories, Burlingame, CA) and subsequently incubated with avidin-biotin-peroxidase complex (Vector Laboratories). Color development was performed with the 0.125% aminoethylcarbazole chromogen substrate solution (Sigma-Aldrich, Union City, CA). For a negative control, all incubation steps were identical except that phosphate-buffered saline rather than primary antibody was used. A previously identified strongly staining tumor tissue section was used as a positive control. The mean percentages of positive tumor cells were determined in at least five areas at Â 100 or Â 200 magnification. Tissues were scored positive when more than 10% of the cells reacted with antisurvivin antibody. The results were analyzed and confirmed by two individuals.
Growth inhibition of human cancer cells in vitro
A transient transfection assay was used to evaluate the cell growth-inhibiting effect of pSRVN-BikDD. In brief, cells were grown in six-well plates with the suggested medium until 60-80% confluent. A fixed amount (50 ng) of pCMV-Luc was cotransfected with 0, 1.5, or 3 mg of pSRVN-BikDD into various human cancer cells per well for 4-6 hours. The final DNA and lipid amounts in each well were kept constant (3.05 mg DNA and 3.05 ml of 8 mM DOTAP:Chol, respectively) by adding an appropriate amount of the pGL3-basic-CD vector. The cells were harvested 48 hours after transfection, and cell lysates were prepared for the luciferase assay. As luciferase activity is indicative of living cells, the relative luciferase activity was used as an index of cell growth and proliferation. 32 For direct measurement of cell viability, live cells of each treatment were counted manually using trypan blue staining (Gibco-BRL) and hemacytometer. For apoptosis assay, Annexin V detection kit (BD Biosciences) was used following the manufacturer's instructions. For Western blot analysis of BikDD expression, cells were harvest 24 hours after transfection.
Tumor growth and treatments in vivo H1299 cells were subcutaneously inoculated into the right dorsal flank of 14 nude mice. When the tumor had reached 4-5 mm 2 (8 days after inoculation), the animals were randomized into two groups (seven mice in each group), and intratumoral treatment was initiated. Group 1 received DOTAP:Chol-pCMV-Luc complex (vector control) and group 2 received DOTAP:Chol-pSRVNBikDD complex (50 mg/dose for each group). Treatments were given every other day for a total of six doses. The tumors were measured every other day, and the tumor volumes were calculated by using the formula V (mm 3
Results
Cancer-specific transgene expression of the survivin promoter in vitro
To assess whether the activation of the survivin promoter is cancer-specific and to compare the cancer-specificity between the survivin promoter and the commonly used CMV promoter, we used pSRVN-Luc and pCMVLuc to determine the activity of the survivin and CMV promoters in cancer and normal cell lines. As shown in Figure 2 , the survivin promoter activity was generally very high in cancer cell lines while very low in normal cell lines. When compared with the activity of the CMV promoter, although the survivin promoter was weaker, the survivin promoter demonstrated greater transgene expression difference between the cancer and normal cell lines, indicating that the survivin promoter is more specifically activated in cancer cells than in normal cells and that the cancer-specificity of transgene expression of the survivin promoter was better than the CMV promoter.
Greater cancer specificity of the survivin promoter than the cmv promoter in vivo
To determine how cancer specific the transgene expression induced by the survivin promoter in vivo is, we established subcutaneous H1299 tumors in nude mice and infused 50 mg/100 ml of pSRVN-Luc or pCMV-Luc into each mouse via the tail vein. The tumors, hearts, lungs, livers, spleens, kidneys, and muscle were removed 48 hours later for luciferase assay. High levels of luciferase activity were detected in the lungs and hearts of the mice treated with pCMV-Luc (Fig 3a) . When compared with the luciferase activity in the tumor, the activity was 42-and 18-fold higher in the lung and heart, respectively. In contrast, the luciferase activity in all the normal tissues of mice treated with pSRVN-Luc was lower than that in tumors (Fig 3b) , and the activity was only 0.19-and 0.48-fold in the lung and heart, respectively. For systemic gene therapy in lung cancers, the expression of therapeutic genes must be high in tumors to increase the genes' antitumor effects, and the expression in normal lung tissue should be low to decrease potential toxicity. Therefore, we defined the cancer-specific index as the luciferase activity of tumors divided by the activity of the lungs. The cancer-specific index was 0.02 for pCMV-Luc, and 5.13 for pSRVN-Luc, indicating that the survivin promoter was more than 200 times more cancer specific than the CMV promoter.
Survivin is expressed in most human non-small-cell lung cancers but not in normal lung tissues
To determine the potential population of lung cancer patients who may benefit from gene therapy with the survivin promoter, the prevalence and expression status of survivin in cancer and normal lung tissues were deter- mined using archived surgical specimens from 75 nonsmall-cell lung cancer patients and 10 normal lung tissues by immunohistochemical staining. Representative pictures of cancer and normal lung tissues are shown in Figure 4 . Survivin staining was mainly located in the cytoplasm. Occasional nuclear staining was also observed. Survivin was expressed in 61 out of 75 (81%) non-smallcell lung cancer specimens but in none of the 10 of normal lung tissues. The prevalence of survivin expression in different subtypes of lung cancers was similar, 80% (37 of 46) in adenocarcinomas, 83% (20 of 24) in squamous cell carcinomas, and 80% (four of five) in adenosquamous carcinomas. These results not only supported the finding that activation of the survivin promoter is cancer specific but also suggested that gene therapy with the survivin promoter can be applied to many lung cancer patients. 
Expression of BikDD driven by the survivin promoter inhibits the cancer cells growth in vitro and in vivo
To evaluate the possibility of using the survivin promoter for in vitro gene therapy, a BikDD expression plasmid containing the survivin promoter (pSRVN-BikDD) was constructed. We performed a transient cotransfection assay to determine the cell growth inhibitory effect of pSRVN-BikDD. As shown in Figure 5a , when compared with the luciferase activity of cells without pSRVNBikDD treatment (0 mg/well), the luciferase activity of three cancer cell lines decreased after treatment of pSRVN-BikDD in a dose-dependent manner. Western blot analysis showed that BikDD was expressed after pSRVN-BikDD transfection (Fig 5b) . To directly measure the growth inhibitory effect of pSRVN-BikDD, vital cells were counted by trypan blue staining and showed that pSRVN-BikDD treatment (3 mg/well) killed 24-30% cells depending on the cell line we used (Fig 5c) . The cellkilling efficiencies are consistent to the transfection efficiencies that are around 30% (data not shown, examined by green fluorescence protein DNA transfection). Annexin-V detection also showed that the pSRVN-BIKDD treatment (3 mg/well) induced apoptosis of cancer cells, although the efficacy was less when compared with pCMV-BIKDD (a 14% killing effect compared to pCMV-BikDD, which induced 30-80% apoptosis of cancer cells, 32 Fig 5d) . These data consistently indicated that the survivin promoter can drive BikDD expression, and induce apoptosis and inhibition of growth in multiple types of cancer cell lines.
To evaluate the possibility of using the survivin promoter for in vivo gene therapy, we established subcutaneous H1299 tumors in nude mice and treated the tumors with pSRVN-BikDD and pCMV-BikDD. After six sequential intratumoral injections of DNA:liposome complexes, the treatment groups of pSRVN-BikDD and pCMV-BIKDD inhibited tumor growth statistically significantly more than did treatment with pCMV-Luc (Fig 5e) . These results demonstrated that the survivin promoter effectively drives BikDD expression in cancer cells and so inhibits the growth of cancer cells in vitro and in vivo.
Discussion
Advanced lung cancer patients usually have compromised pulmonary function because of a long history of smoking or tumor-associated respiratory insufficiency. Targeted expression of therapeutic genes with reduced toxicity of major organs, especially in the lungs, is critical for systemic gene therapy of these patients. Among the numerous targeted gene strategies, control of gene expression via tissue-or cancer-specific promoters is an attractive strategy and has been tested extensively. By using nonspecific prokaryotic promoters such as the CMV promoter delivered by cationic liposomes, the levels of transgene expression in normal lung tissues could be as high as 100-fold compared with distant tumors. 35 Our data also revealed that the ratio of the CMV promoter activity in the lung and heart was 42-and These data consistently demonstrated that the CMV promoter is highly activated in normal lung tissues and may contribute to pulmonary toxicity when used in systemic gene therapy. The expression of survivin is noted in common human cancers but not in normal adult tissues. Since the increased survivin activity is controlled transcriptionally, it has been suggested that the survivin promoter might control the transgene expression in a cancer-specific manner. 23 However, this hypothesis has never been proved in vivo. In the study reported here, we demonstrated that the survivin promoter was strongly activated in various cancer cell lines but repressed in normal cell lines and tissues, especially in the lungs. In fact, the activity of the survivin promoter expression in the normal tissues of the heart, lung, liver and kidney was very low, with almost no expression when compared with the background. These results suggest that when a systemically administered suicide gene is driven by the survivin promoter, the systemic toxicity could be significantly reduced.
Most cancer-specific promoters are only activated in a limited population of tumor histologies. To determine whether the survivin promoter can be applied universally in gene therapy of lung cancer patients, survivin protein expression was evaluated by immunohistochemical staining in surgical specimens of 75 NSCLC patients. Consistent with two previous publications that demonstrated that over than 95% NSCLC samples examined strongly overexpressed survivin mRNA and protein compared with a nontumor control, 10, 25 and that the survivin protein was overexpression in most of the NSCLC specimens (81%) regardless of histological subtypes. In addition, the general activation of the survivin promoter and similar inhibitory effects of the pSRVN-BikDD in lung, colon, and cervical cancer cell lines also suggested that using the survivin promoter in gene therapy may benefit patients with many kinds of cancer. Furthermore, the depressed expression of survivin in all normal lung tissues also supports our hypothesis that the activation of the survivin promoter is cancerspecific and, when used in gene therapy, could reduce the pulmonary toxicity.
Another limitation of cancer-specific promoters is that most of these promoters are much weaker than commonly used viral promoters such as the CMV promoter or the SV40 promoter. 36 Although the activity of the survivin promoter was about 10 to 40 % of the CMV promoter in all cancer cells tested, the transgene expression of the survivin promoter was 2-to 10-fold higher than the SV40 promoter (data not shown). A previous report also showed that the survivin promoter is 2-3-fold more active than the SV40 promoter, 23 suggesting that the survivin promoter can induce high transgene expression in cancer cells.
In summary, our study demonstrated that the activation of the survivin promoter is cancer specific and can effectively induce transgene expression in cancer cell lines and xenograft tumors. The survivin promoter can also drive expression of BikDD in cancer cells inhibiting cancer cell growth in vitro and in vivo. As survivin expression is commonly expressed in lung cancer specimens and various cancer cell lines, the survivin promoter may be useful in cancer gene therapy. 
